Gallbladder Cancer Clinical Trials (2026): 32 Recruiting Interventional Studies

Last updated: March 10, 2026

Current Clinical Trial Landscape

Recruiting Trials by Treatment Setting

Neoadjuvant Therapy

Before surgery for locally advanced disease:

• NCT06712420 - Neoadjuvant chemotherapy for locally advanced gallbladder cancer (Phase 3)

First-Line Metastatic/Unresectable

For previously untreated advanced disease:

• NCT07221253 - Rilvegostomig or durvalumab + chemotherapy (Phase 3)
• NCT07265674 - Novel combination vs standard of care (Phase 3)
• NCT06529718 - Ivonescimab vs FOLFOX (Phase 2)

Second-Line and Beyond

After progression on first-line therapy:

• NCT07146646 - Trifluridine/tipiracil + oxaliplatin (Phase 2)
• NCT07025174 - Sequential anti-angiogenic therapy after immunotherapy

Trials by Treatment Approach

Immunotherapy Combinations

Checkpoint inhibitors with chemotherapy or other agents:

• NCT06423170 - Camrelizumab combination (Phase 2)
• NCT05757336 - Gemcitabine + albumin-paclitaxel + sintilimab + bevacizumab

HER2-Targeted Therapy

For HER2-positive gallbladder cancer (~15-20%):

• NCT06282575 - Zanidatamab + standard of care (Phase 3)
• NCT05786716 - Trastuzumab + pertuzumab (DETERMINE Trial)
• NCT06178445 - GemCis + trastuzumab + pembrolizumab (Phase 2)

KRAS-Targeted Therapy

• NCT07023731 - ARV-806 for KRAS G12D mutations (Phase 1/2)

Regional Therapies

Hepatic arterial infusion and radiation:

• NCT06852287 - GemOX hepatic arterial infusion + lenvatinib + PD-1 (Phase 2)
• NCT06214572 - Radiation therapy in unresectable gallbladder cancer

Novel Targeted Agents

• NCT05833815 - Everolimus + standard of care (mTOR inhibitor)
• NCT04183712 - Targeted therapy + GEMOX with ctDNA monitoring
• NCT05732831 - TNG462 for MTAP-deleted tumors
• NCT04585750 - PC14586 for TP53 mutations

View all 32 gallbladder cancer trials on ClinicalTrials.gov →

Trial listings from ClinicalTrials.gov. Page summaries generated by AI and may contain errors. Always verify with your healthcare provider.